진행성 악성종양별 맞춤 항암요법의 최신 지견 ; 위암의 맞춤 항암 요법의 최신 지견 = Special Review : Recent advance in tailored treatment of gastric cancer

다국어 초록 (Multilingual Abstract)

Even the overall incidence is decreasing and the proportion of early gastric cancer is increasing from the national mass screening program, still gastric cancer is the major issue in Korea. Multimodality approach and the development of novel therapeutic agents enabled us to improve the survival rate of gastric cancer. However, the proper treatment strategy for the subgroups of patients is necessary, which is now categorized based on the clinicopathologic parameters. We need more in-depth information regarding the molecular biology of gastric cancer, and the development of novel targeted biological agents and the biomarkers for the future. Currently, the recent chemotherapeutic agents showed the improved response in advanced gastric cancer. Hence, the basic concept of adjuvant chemotherapy, palliative chemotherapy, neoadjuvant treatment with or without incorporation of radiotherapy become settle down with more evidences from several phase III trials. Especially, after understanding the difference between Asia and Western countries including biology, ethnic difference, operation technology, and the treatment approaches, the qualified, well-designed multinational clinical trials are on-going. Based on the current results, here, I describe the current status of gastric cancer treatment strategy. (Korean J Med 77:1-8, 2009)

참고문헌 (Reference)

1 Van Cutsem E, "V325 Study Group. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 study group" 24 : 4991-4997, 2006

2 Van Cutsem E, "The treatment of advanced gastric cancer: new findings on the activity of the taxanes" 9 (9): 9-15, 2004

3 Van Cutsem E, "The treatment of advanced gastric cancer: new findings on the activity of the taxanes" 9 (9): 9-15, 2004

4 Koizumi W, "S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial" 9 : 215-221, 2008

5 Kang Y, "Randomized phase III trial of capecitabine/cisplatin (XP) vs. Continuous infusion of 5-FU/cisplatin (FP) as first-line therapy in patients with advanced gastric cancer (AGC)" 24 : 17S-, 2006

6 Boku N, "Randomized phase III study of 5-fluorouracil (5-FU) alone versus combination of irinotecan and cisplatin (CP) versus S-1 alone in advanced gastric cancer (JCOG9912)" 25 : 18S-, 2007

7 Dank M, "Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction" 19 : 1450-1457, 2008

8 Ajani JA, "Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response" 24 : 3953-3958, 2006

9 Cunningham D, "Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer" 355 : 11-20, 2006

10 Ajani JA, "Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially respectable gastric carcinoma" 22 : 2774-2780, 2004

11 Ohtsu A, "Japan Clinical Oncology Group Study (JCOG9205). Randomized phase III trial of 5-fluorouracil alone versus 5-fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin C in patients with unresectable advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205)" 21 : 54-59, 2003

12 Vanhoefer U, "Final result of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin, versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group" 81 : 2648-2657, 2000

13 Van Cutsem, "Efficacy results from the ToGA trial: a phase III study of trastzumab added to standard chemotherapy in first-line human epidermal growth factor receptor2 (HER-2)-positive advnaced gastric cancer" 27 : S15-, 2009

14 Di Cosimo S, "Docetaxel in advanced gastric cancer" 42 : 693-700, 2003

15 Ohtsu A, "Chemotherapy for metastatic gastric cancer: past, present, and future" 43 : 256-264, 2008

16 Macdonald J, "Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal function" 345 : 725-730, 2001

17 Cunningham D, "Capecitabine and oxaliplatin for advanced esophagogastric cancer" 358 : 36-46, 2008

18 Sakuramoto S, "Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine" 357 : 1810-1820, 2007

19 Jeung HC, "Adjuvant 5-fluorouracil plus doxorubicin in D2-3 resected gastric carcinoma: 15-year experience at a single institute" 91 : 2016-2025, 2001

20 Kim NK, "A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer" 71 : 3813-3818, 1993

21 Hai-Rim Shin, "2002 Annual Report of the Korea Central Cancer Registry: Based on Registered Data from 139 Hospitals" 대한암학회 36 (36): 103-114, 2004